4.8 Article

HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology

期刊

CANCER RESEARCH
卷 76, 期 22, 页码 6598-6606

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-16-0633

关键词

-

类别

资金

  1. GlaxoSmithKline Ltd.
  2. Health and Social Research Development Division of the Public Health Agency
  3. University of Liverpool
  4. Aintree University Hospitals NHS Foundation Trust
  5. Cancer Research UK [17161] Funding Source: researchfish
  6. National Institute for Health Research [NF-SI-0515-10101, RP-PG-0707-10034, CL-2013-07-002, NF-SI-0513-10083, ACF-2016-07-006, ACF-2012-07-007, NIHR-RP-011-045] Funding Source: researchfish
  7. Public Health Agency [SPI/5151/15] Funding Source: researchfish

向作者/读者索取更多资源

A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative OPSCC within the United Kingdom. Archival tumor tissue blocks from 1,602 patients previously diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with three validated commercial tests to provide valid data for 1,474 cases in total. Corresponding national incidence data from the same decade were obtained from UK Cancer registries. The overall proportion of HPV+ OPSCC between 2002 and 2011 was 51.8% [95% confidence interval (CI), 49.3-54.4], and this remained unchanged throughout the decade [unadjusted RR = 1.00 (95% CI, 0.99-1.02)]. However, over the same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase [age-standardized rate 2002: 2.1 (95% CI, 1.9-2.2); 2011: 4.1 (95% CI, 4.0-4.3)]. Although the number of OPSCCs diagnosed within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV+ cases remained static at approximately 50%. Our results argue that the rapidly increasing incidence of OPSCC in the United Kingdom cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV+ cases we documented warrants further investigation, so that appropriate future prevention strategies for both types of disease can be implemented. (C) 2016 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Systematic review and meta-analysis of occult contralateral nodal metastases in patients with oropharyngeal squamous carcinoma undergoing elective neck dissection

Akshat Malik, John C. Hardman, Yadsan Devabalan, Christopher Nutting, Shreerang Bhide, Kevin Harrington, Clare Schilling, Vinidh Paleri

Summary: A systematic review and meta-analysis was conducted to evaluate occult contralateral nodal metastases (OCM) in patients undergoing bilateral neck dissection for surgically treated oropharyngeal squamous cell carcinoma (OPSCC). The study found that OCM were seen in 9.8% of patients, with a higher rate in cN positive necks compared to cN0 necks. This highlights the importance of considering contralateral neck involvement in the surgical treatment of OPSCC.
Article Oncology

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin

Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Dentistry, Oral Surgery & Medicine

Surgical sequence, timing and volume, and variation in dento-facial outcome, speech and secondary surgery in children with unilateral cleft lip and palate: The Cleft Care UK Study

Rona Slator, Lydia Perisanidou, Debbie Sell, Jonathan Sandy, Andrew R. Ness, Andrew K. Wills

Summary: This study found associations between surgical variables and speech outcomes at 5 years of age, but not between surgical variables and dento-facial outcome, nor between surgical variables and secondary speech surgery.

ORTHODONTICS & CRANIOFACIAL RESEARCH (2023)

Article Oncology

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Charles M. Rudin, Hardev S. Pandha, Matthew Zibelman, Wallace L. Akerley, Kevin J. Harrington, Daphne Day, Andrew G. Hill, Steven J. O'Day, Timothy D. Clay, Gavin M. Wright, Ross R. Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Jaime R. Merchan, Yixin Ren, Emmett Schmidt, Lisa Guttman, Sumati Gupta

Summary: This study evaluated the efficacy and safety of V937 combined with pembrolizumab in patients with advanced solid tumors. The results showed that the combination therapy had a manageable safety profile, but did not achieve greater efficacy than pembrolizumab monotherapy in non-small cell lung cancer and urothelial cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Genetics & Heredity

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Burcu F. Darst, Jiayi Shen, Ravi K. Madduri, Alexis A. Rodriguez, Yukai Xiao, Xin Sheng, Edward J. Saunders, Tokhir Dadaev, Mark N. Brook, Thomas J. Hoffmann, Kenneth Muir, Peggy Wan, Loic Le Marchand, Lynne Wilkens, Ying Wang, Johanna Schleutker, Robert J. MacInnis, Cezary Cybulski, David E. Neal, Borge G. Nordestgaard, Sune F. Nielsen, Jyotsna Batra, Judith A. Clements, Henrik Gronberg, Nora Pashayan, Ruth C. Travis, Jong Y. Park, Demetrius Albanes, Stephanie Weinstein, Lorelei A. Mucci, David J. Hunter, Kathryn L. Penney, Catherine M. Tangen, Robert J. Hamilton, Marie-Elise Parent, Janet L. Stanford, Stella Koutros, Alicja Wolk, Karina D. Sorensen, William J. Blot, Edward D. Yeboah, James E. Mensah, Yong-Jie Lu, Daniel J. Schaid, Stephen N. Thibodeau, Catharine M. West, Christiane Maier, Adam S. Kibel, Geraldine Cancel-Tassin, Florence Menegaux, Esther M. John, Eli Marie Grindedal, Kay-Tee Khaw, Sue A. Ingles, Ana Vega, Barry S. Rosenstein, Manuel R. Teixeira, Manoli Kogevinas, Lisa Cannon-Albright, Chad Huff, Luc Multigner, Radka Kaneva, Robin J. Leach, Hermann Brenner, Ann W. Hsing, Rick A. Kittles, Adam B. Murphy, Christopher J. Logothetis, Susan L. Neuhausen, William B. Isaacs, Barbara Nemesure, Anselm J. Hennis, John Carpten, Hardev Pandha, Kim De Ruyck, Jianfeng Xu, Azad Razack, Soo-Hwang Teo, Lisa F. Newcomb, Jay H. Fowke, Christine Neslund-Dudas, Benjamin A. Rybicki, Marija Gamulin, Nawaid Usmani, Frank Claessens, Manuela Gago-Dominguez, Jose Esteban Castelao, Paul A. Townsend, Dana C. Crawford, Gyorgy Petrovics, Graham Casey, Monique J. Roobol, Jennifer F. Hu, Sonja I. Berndt, Stephen K. van den Eeden, Douglas F. Easton, Stephen J. Chanock, Michael B. Cook, Fredrik Wiklund, John S. Witte, Rosalind A. Eeles, Zsofia Kote-Jarai, Stephen Watya, John M. Gaziano, Amy C. Justice, David V. Conti, Christopher A. Haiman

Summary: In this study, the predictive ability of several genome-wide polygenic risk score (GW-PRS) approaches was compared to a recently developed PRS of established prostate cancer-risk variants. The findings suggest that the PRS269 developed from multi-ancestry GWASs and fine-mapping has better predictive ability for prostate cancer risk compared to current GW-PRS approaches.

AMERICAN JOURNAL OF HUMAN GENETICS (2023)

Review Oncology

Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

Robert I. Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y. Lee

Summary: For the last 20 years, cisplatin-based chemoradiotherapy has been the standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) patients at high risk of recurrence. However, many patients are ineligible for this treatment due to various reasons. The criteria for cisplatin ineligibility, including age and renal impairment, are still debated. The proportion of cisplatin ineligible patients with resected LA SCCHN remains unclear. This review discusses cisplatin ineligibility considerations, limited clinical evidence, and ongoing clinical trials for alternative treatment options.

CANCER TREATMENT REVIEWS (2023)

Review Otorhinolaryngology

The role of transoral surgery in the diagnosis of the carcinoma of unknown origin of the head and neck

Hisham Mehanna

Summary: The purpose of this article is to provide readers with the latest evidence on the role of trans oral surgery (TOS) in diagnosing carcinoma of unknown primary in the head and neck. Recent findings suggest that tongue base mucosectomy is important in identifying the primary site in patients with negative imaging, PET CT scans, and ipsilateral tonsillectomy. There are still unanswered questions regarding the sequencing of operations and the use of intraoperative frozen section. An evidence-based approach to diagnosis is crucial in order to achieve higher detection rates and minimize morbidity in patients with head and neck carcinoma of unknown primary.

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY (2023)

Article Medicine, General & Internal

Conservative management versus tonsillectomy in adults with recurrent acute tonsillitis in the UK (NATTINA): a multicentre, open-label, randomised controlled trial

Janet A. Wilson, James O'Hara, Tony Fouweather, Tara Homer, Deborah D. Stocken, Luke Vale, Catherine Haighton, Nikki Rousseau, Rebecca Wilson, Lorraine Mcsweeney, Scott Wilkes, Jill Morrison, Kenneth Mackenzie, Kim Ah-See, Sean Carrie, Claire Hopkins, Nicola Howe, Musheer Hussain, Hisham Mehanna, Christopher Raine, Frank Sullivan, Alexander von Wilamowitz-Moellendorff, M. Dawn Teare

Summary: This study compares the clinical effectiveness and cost-effectiveness of conservative management and tonsillectomy in adults with recurrent acute tonsillitis. The results show that immediate tonsillectomy is more effective in reducing sore throat days and has better cost-effectiveness compared to conservative management.

LANCET (2023)

Article Oncology

Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis

Hisham Mehanna, Miren Taberna, Christian von Buchwald, Sara Tous, Jill Brooks, Marisa Mena, Francisca Morey, Christian Gronhoj, Jacob Hoygaard Rasmussen, Martin Garset-Zamani, Laia Bruni, Nikolaos Batis, Ruud H. Brakenhoff, C. Rene Leemans, Robert J. Baatenburg de Jong, Jens Peter Klussmann, Nora Wuerdemann, Steffen Wagner, Tina Dalianis, Linda Marklund, Haitham Mirghani, Andrew Schache, Jaqueline A. James, Shao Hui Huang, Brian O'Sullivan, Paul Nankivell, Martina A. Broglie, Markus Hoffmann, Elgar Susanne Quabius, Laia Alemany

Summary: The study aimed to quantify the discordance between p16 expression and HPV status in oropharyngeal cancer and evaluate its prognostic implications. The results showed that patients with p16-/HPV+ or p16+/HPV- had worse prognosis compared to p16+/HPV+ or p16-/HPV- patients. HPV testing should be mandatory in clinical trials and recommended in patient care settings where HPV status may have an impact.

LANCET ONCOLOGY (2023)

Review Oncology

Systematic review of patients' and healthcare professionals' views on patient-initiated follow-up in treated cancer patients

Janine Dretzke, Ava Lorenc, Ada Adriano, Clare Herd, Hisham Mehanna, Paul Nankivell, David J. Moore

Summary: The current follow-up models in cancer are seen as unsustainable and inflexible. Patient-initiated follow-up (PIFU) is gaining interest as an alternative model, and it is important to determine its acceptability to patients and healthcare professionals (HCPs). The findings show that most women treated for breast or endometrial cancer and HCPs support PIFU, but further research is needed.

CANCER MEDICINE (2023)

Article Oncology

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

P. Martin, Z. Tsourti, J. Ribeiro, L. Castelo-Branco, E. de Azambuja, S. Gennatas, J. Rogado, M. Sekacheva, S. Susnjal, D. Vinal, R. Lee, S. Khallaf, G. Dimopoulou, S. Pradervand, J. Whisenant, T. K. Choueiri, D. Arnold, K. Harrington, K. Punie, J. Oliveira, O. Michielin, U. Dafni, S. Peters, G. Pentheroudakis, E. Romano

Summary: This paragraph summarizes the results of a study analyzing COVID-19 patients, which found that factors such as symptomatic patients, males, older age, ethnicity other than Asian/Caucasian, Eastern Cooperative Oncology Group performance status >2, body mass index <25, hematological malignancy, progressive disease versus no evident disease, and advanced cancer stage significantly affect COVID-19 outcomes.

ESMO OPEN (2023)

Article Oncology

Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma

Alexandra J. Rose, Mercedes M. Fleming, Jeffrey C. Francis, Jian Ning, Anton Patrikeev, Ritika Chauhan, Kevin J. Harrington, Amanda Swain

Summary: This study established patient-derived xenograft (PDX) lines and tumor organoid models for salivary gland adenoid cystic carcinoma (ACC), and demonstrated the inhibitory effect of dBET6 on ACC cells. Molecular studies revealed a decrease in BRD4 and MYB protein levels and target gene expression with dBET6 treatment. In vivo experiments showed that dBET6 altered the relative composition of ACC cell types and inhibited their progenitor function.

JOURNAL OF PATHOLOGY (2023)

Article Otorhinolaryngology

Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer

Joseph Califano, Andrew Yousef, Heba Mostafa, Alexandra Valsamakis, Xinlian Zhang, Nikolaos Batis, Christy Varghese, Joanna Parish, Michael Forman, Junko Jarrett, Karen Messer, Hisham Mehanna

Summary: The objective of this study was to identify low-risk HPV-related oropharyngeal cancer (HPVOPC) patients at risk of recurrence by detecting HPV16 DNA in plasma and salivary rinses. The combined plasma and salivary HPV DNA assays showed a sensitivity of 65% and a specificity of 87% in detecting recurrence, with a median lead time of 19 days. Therefore, the presence of HPV DNA in post-treatment plasma and salivary rinses is associated with recurrence, providing a potential opportunity for earlier detection.

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2023)

Article Dentistry, Oral Surgery & Medicine

Head and neck mucosal melanoma: radiological considerations and UK imaging guidelines

Ashwin Algudkar, Kevin Harrington, Cyrus Kerawala, Izhar Bagwan, Derfel Ap Dafydd

Summary: This study summarizes the imaging recommendations and characteristics of head and neck mucosal melanoma (HNMM), and provides revised guidelines to guide the investigation and management of this rare and aggressive cancer.

ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG (2023)

Article Oncology

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence

K. J. Harrington, E. E. W. Cohen, D. Soulieres, J. Dinis, L. Licitra, M. -j. Ahn, A. Soria, J. -p. Machiels, N. Mach, R. Mehra, B. Burtness, R. F. Swaby, J. Lin, J. Ge, N. Lerman, C. Le Tourneau

Summary: Through a study on patients with HNSCC, it was found that pembrolizumab provided longer overall survival and durable responses in all subgroups of recurrence patterns, regardless of previous treatment.

ORAL ONCOLOGY (2023)

暂无数据